Home » 26 listed pharmaceutical and biological companies reported that consumer medical and innovative drugs performed outstandingly in the report-Finance News

26 listed pharmaceutical and biological companies reported that consumer medical and innovative drugs performed outstandingly in the report-Finance News

by admin


For stocks, look at the research report of Golden Unicorn analysts, authoritative, professional, timely and comprehensive, to help you tap potential thematic opportunities!

26 listed pharmaceutical and biological companies reported that consumer medical and innovative drugs performed outstandingly in the report

Securities Daily Network The Voice of Securities Daily

As of June 29, 43 listed companies in the pharmaceutical and biological sector of the Shenwan industry have announced their performance forecasts for the first half of 2020, of which 26 companies are expected to increase their net profit attributable to shareholders of listed companies year-on-year.Among them, such as the upstream of the medical beauty industry chainHaohaishengke, The net profit attributable to shareholders of listed companies is expected to increase by more than 600% year-on-year. Innovative vaccine research and development companiesCancinoExpected to turn around in the first half of the year.

Zhang Cuixia, chief investment consultant of Jufeng Investment, told the “Securities Daily” reporter that the current medical aesthetics consumer market has a huge space. Data shows that from 2014 to 2019, the size of my country’s medical aesthetics market has grown from 52.1 billion yuan to 152.1 billion yuan. The growth rate is as high as about 25%. Moreover, my country has become the world’s second largest consumer market for medical aesthetics. As an upstream supplier of medical aesthetics, we will fully enjoy the industry’s growth dividends.

See also  CO2 emissions: Germany should reduce three times faster | Germany | DW

Zhang Cuixia said: “Because of the combination of medical technology innovation and the medical aesthetics industry, the past high-end medical aesthetics services have moved to the general consumer level, bringing unprecedented development prospects. The core listed companies of medical aesthetics in the true sense of A-shares are often the finest companies. The leading companies in different fields can achieve breakthroughs in performance and be recognized by capital. Similarly, when medical technology and consumption are combined, they often trigger the large-scale growth of the industry. Fields such as ophthalmology and dentistry have similar logic. The semi-annual report performance and market performance of companies in the consumer medical field are worthy of attention.”

The performance of R&D pharmaceutical companies in the first half of the year was also outstanding. Cansino, which was listed on the fifth set of standards on the Science and Technology Innovation Board, has continued to lose money since 2017. In the first half of this year, the company turned losses into profits for the first time. .

Gong Tao, chairman of Shenzhen Zhongjin Huachuang Fund, believes that although innovative drug R&D companies are high-risk and high-return companies, they benefit from my country’s policy guidance to encourage drug R&D and provide relevant companies both in terms of taxation and industrial support. Rich policy dividends have enabled such companies to grow rapidly with the dual support of policy and capital.

Gong Tao told reporters that in recent years, many R&D pharmaceutical companies have successfully gone public and even landed in the capital market without making a profit. With the support of capital, the transformation of R&D results has been accelerated and their performance has been achieved. In this regard, investors should invest in companies with high growth potential after clearly seeing the general direction of pharmaceutical innovation, and implement strategies to diversify their investments.

See also  Warren Buffett Remains Unfazed by Fitch Ratings' Downgrade of U.S. Credit Rating

The reporter combed through the listed companies in the pharmaceutical and biological sector that have issued performance forecasts and found that the performance of pharmaceutical companies is better than that of listed medical service companies, and even some medical service companies have continued to lose money this year. Gong Tao believes that it is too early to conclude that the interim reports of pharmaceutical companies are better than medical service companies, because some listed private hospitals have not announced performance forecasts, and they are the leading companies in the medical service industry.

Tian Xinjie, a medical researcher at Senrui Investment, analyzed to a reporter from the Securities Daily that from the perspective of performance growth, because pharmaceutical companies were more affected by the epidemic last year, they grew faster year-on-year as their operations improved. Therefore, it needs to be compared with the base situation in 2019, especially with the normalization of centralized procurement, which puts more pressure on the performance of pharmaceutical companies.

Tian Xinjie said: “Pharmaceutical companies that are more affected by centralized procurement have relatively low market expectations for their performance and investment. Generally speaking, the more types of companies involved in centralized procurement in the future, the greater the risk, so they can enjoy market dividends. It is declining. Some pharmaceutical companies are actively engaged in research and development, and domestic innovative drugs are currently in the stage of outbreaks and some new drugs have just landed. The performance is not much realized. Although it gives investors and the market great confidence, At the same time, the competition for pharmaceutical market share is also more encouraging, and it is also necessary to pay attention to the risks of bubbles and high performance.

See also  Tencent Tang Daosheng: Large-scale models are just the starting point, and industrial implementation is a bigger application scenario of AI- DoNews

Is the bull market coming? How to get on the bus quickly, the gold medal investment advisory service is free >>


Sina statement: This news is reprinted from Sina’s cooperative media. The publication of this article on Sina.com is for the purpose of conveying more information and does not mean that it agrees with its views or confirms its description. Article content is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.

Massive information, accurate interpretation, all in Sina Finance APP

Editor in charge: Yang Hongbu

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy